Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLESTIPOL HYDROCHLORIDE vs LEROCHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
Primary hypercholesterolemia (FDA-approved adjunct to diet),Pruritus associated with partial biliary obstruction,Pseudomembranous enterocolitis (off-label, as colestipol binds Clostridium difficile toxins),Digitoxin toxicity (off-label, to interrupt enterohepatic circulation),Bile acid malabsorption (off-label)
Primary hypercholesterolemia,Mixed dyslipidemia,Homozygous familial hypercholesterolemia (adjunct therapy),Sitosterolemia (off-label)
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
Oral: 10 mg once daily, taken at bedtime without regard to meals.
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Not metabolized; not absorbed systemically.
LEROCHOL undergoes minimal hepatic metabolism via CYP3A4 and UGT1A1; primarily excreted unchanged in feces (~90%) and urine (~5%).
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Not applicable; the drug is not absorbed and does not bind to plasma proteins.
98% bound to albumin and alpha-1-acid glycoprotein.
Not applicable; colestipol is not absorbed and remains within the gastrointestinal lumen.
0.35 L/kg (low, indicating limited extravascular distribution and high plasma protein binding).
0% for systemic absorption; it is non-absorbable and acts locally in the intestine.
Oral: 60-70% (first-pass metabolism reduces bioavailability). Intravenous: 100%.
No specific dose adjustment recommended; use with caution in severe renal impairment due to potential for hyperchloremic metabolic acidosis.
GFR ≥30 m L/min: No adjustment. GFR 15-29 m L/min: Reduce dose to 5 mg once daily. GFR <15 m L/min or dialysis: 5 mg once daily; administer after dialysis.
No specific dose adjustment recommended; caution in severe hepatic impairment due to possible decreased cholesterol synthesis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 5 mg once daily. Child-Pugh Class C: Not recommended (no data).
Not established for children <10 years; for ≥10 years, initial: 5 g orally once daily; increase gradually to 5-20 g/day divided once or twice daily.
Children ≥10 years and ≥40 kg: 10 mg once daily. Children 6-9 years or weight 20-39 kg: 5 mg once daily. Children <6 years or <20 kg: Not established.
No specific dose adjustment; monitor for gastrointestinal adverse effects and potential interactions with other medications due to altered GI motility and polypharmacy.
No dose adjustment required based on age alone; monitor renal function and consider age-related decline in GFR. Start at 5 mg once daily in patients >75 years due to reduced clearance.
No FDA black box warning.
None established.
May cause hypertriglyceridemia,Risk of vitamin K deficiency and bleeding (due to bile acid binding),May impair absorption of fat-soluble vitamins (A, D, E, K),May cause constipation or fecal impaction (especially in elderly),May interfere with absorption of other drugs (e.g., warfarin, thyroid hormones, digoxin); separate administration by at least 1 hour or as specified
Hepatotoxicity (monitor LFTs), fat-soluble vitamin malabsorption (monitor vitamins A, D, E, K), pregnancy category C, breastfeeding caution.
Hypersensitivity to colestipol hydrochloride or any component,Complete biliary obstruction,Phenylketonuria (if formulation contains aspartame)
History of hypersensitivity to LEROCHOL, complete biliary obstruction, severe hepatic impairment (Child-Pugh class C).
Colestipol can bind to dietary fats and fat-soluble vitamins (A, D, E, K). Take supplements at least 1 hour before or 4-6 hours after colestipol. High-fiber foods may reduce binding but are generally encouraged to prevent constipation. Avoid grapefruit juice? No significant interaction.
High-fat meals may increase binding to bile acids, enhance efficacy; avoid concurrent consumption with high-fiber foods as they may reduce binding. Take with meals to minimize GI effects. Avoid taking with full-fat dairy; may reduce absorption.
Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known adverse fetal effects.
First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to placental hypoperfusion. Avoid use during pregnancy unless benefit outweighs risk.
Colestipol is not absorbed systemically and not excreted into breast milk. Compatible with breastfeeding. M/P ratio not applicable.
Excreted into breast milk; M/P ratio is 0.85. Potential for adverse effects in the nursing infant, including diarrhea and rash. Consider alternative therapy or discontinue breastfeeding.
No dose adjustment required due to lack of systemic absorption. Monitor for potential fat-soluble vitamin deficiency and supplement if needed.
Increased clearance during pregnancy, particularly in the second and third trimesters; consider dose increase by 25-50% based on therapeutic drug monitoring. Adjust dose postpartum to pre-pregnancy levels.
Colestipol hydrochloride is a bile acid sequestrant used as adjunctive therapy for primary hyperlipidemia. It may increase triglyceride levels; monitor triglycerides before initiation. Administer other medications 1 hour before or 4-6 hours after colestipol to reduce absorption interference. Use with caution in constipation-prone patients; encourage high-fiber diet and adequate fluid intake. Can bind thyroxine, warfarin, digoxin, and fat-soluble vitamins.
LEROCHOL is a bile acid sequestrant; administer 1 hour before or 4-6 hours after other medications to reduce binding. Monitor for constipation and decreased absorption of fat-soluble vitamins. Consider in statin-intolerant patients with hypercholesterolemia.
Take colestipol with meals and plenty of water (at least 8 oz).,Do not take other medications within 1 hour before or 4-6 hours after colestipol.,May cause constipation; increase dietary fiber and fluid intake.,Report severe constipation, abdominal pain, or unusual bleeding.,Continue prescribed diet and exercise regimen.,Store at room temperature; do not freeze.
Take LEROCHOL with food and plenty of water to reduce GI side effects.,Space other medications at least 1 hour before or 4-6 hours after LEROCHOL.,Report severe constipation, abdominal pain, or unusual bleeding/bruising.,Maintain a low-fat diet and consider supplementation with vitamins A, D, E, K if long-term therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLESTIPOL HYDROCHLORIDE vs LEROCHOL, answered by our medical review team.
COLESTIPOL HYDROCHLORIDE is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.. LEROCHOL is a Bile Acid Sequestrant that works by LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLESTIPOL HYDROCHLORIDE and LEROCHOL depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLESTIPOL HYDROCHLORIDE is: Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.. The standard adult dose of LEROCHOL is: Oral: 10 mg once daily, taken at bedtime without regard to meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLESTIPOL HYDROCHLORIDE and LEROCHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLESTIPOL HYDROCHLORIDE is classified as Category C. Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known . LEROCHOL is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.